Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ: BBIO )

34.90 +3.34 (+10.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Top 4 Health Care Stocks You May Want To Dump In Q1
Via Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
Why BridgeBio Pharma Stock Is Trading Lower Tuesday
BridgeBio Pharma, Inc. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Via Benzinga
Topics Economy
Exposures Fossil Fuels Interest Rates
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Via Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel. 
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality. 
Via Benzinga
Exposures Product Safety
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November... 
Via Benzinga
Exposures Product Safety
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key... 
Via Benzinga
Patchy And Still Patchy In The Short Term
In the very short term, I would say the further downside is likely but not for long. These are not ideal conditions, so either sit it out or make sure you take your profits early. 
Via Talk Markets
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... 
Via Benzinga
Marvell Technology Posts Upbeat Sales, Joins MongoDB, Intel, MINISO Group And Other Big Stocks Moving Higher On Friday
Via Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented... 
Via Benzinga
BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024
BBIO stock results show that BridgeBio Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Via Benzinga
Masters In Trading - Saturday, June 22
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
The 3 Best Biotech Stocks to Buy in June 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body... 
Via Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine. 
Via Investor's Business Daily
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
BBIO stock results show that BridgeBio Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
What's Going On With BridgeBio Pharma Stock On Monday?
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback